TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Antimicrobial Activity of Omiganan 1% Gel vs. Chlorhexidine 2% for Topical Skin Antisepsis in Healthy Adult Subjects

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects18-70 years of age~* No evidence of dermatosis, dermatitis, inflammation, scarring, or acute injuries to the drug application sites on the chest or abdomen~* Subjects must have screening samples from the skin on the right and left side of the chest or abdomen containing at least 2.5 log10 colony forming units per square centimeter (CFU/cm2 )organisms (from the average of 2 samples obtained during screening)~* Willing to provide written informed consent.~Exclusion Criteria:~* Allergies or sensitivities to alcohol, adhesive tape, bandages, latex, chlorhexidine gluconate, or any of the ingredients of omiganan 1% gel~* Prior treatment with any systemic antibiotic, or any other product known to affect the normal microbial flora of the skin within 7 days of the screening examination~* Requirement for topical antibiotic use on or within 10 cm of any study test site~* Subjects who have been treated with any investigational drug (other than omiganan) within the previous 30 days, or who are participating in an investigational drug study at any time during the course of this study~* Subjects who have been previously treated with omiganan and experienced a possibly related adverse event during the study Note: a wash out period of one week is required prior to participation in Part 2 of the study~* A medical condition that the Investigator believes may interfere with the safety of the subject or the intent and conduct of the study Note: this includes conditions such as: severe eczema, psoriasis and/or dermal infections, old scars, insulin dependent diabetes mellitus, severe immunocompromising conditions, HIV infection, or use of medications that would interfere with assessment of study endpoints~* A current or recent history of illicit drug or alcohol abuse~* Subjects not willing or able to fulfill protocol requirements~* Pregnancy. Women of childbearing potential who have a positive or equivocal result on a urine and/or blood pregnancy test before study enrollment will not be included

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- omiganan 1% gel (Type: EXPERIMENTAL): Omiganan has a rapid bactericidal and fungicidal effect which is under development for the prevention of infections arising from short-term central venous catheters, as well as for the prevention of surgical wound infections in contaminated wounds.
- chlorhexidine 2% (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: IOP-Lowering Efficacy of Brinzolamide 1.0% Added to Travoprost 0.004%/Timolol 0.5% Fixed Combination as Adjunctive Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Glaucoma~Exclusion Criteria:~* Under 18

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mayo Acute Stroke Trial for Enhancing Recovery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Definite or probable acute ischemic cerebrovascular syndrome (AICS), as defined by Kidwell et al (Stroke. 2003;34:2995-8).~* Experimental treatment started within 24 hours of onset of symptoms.~* Age ≥ 18 years.~* Ability and willingness to return for follow-up visits.~* Willingness of an available informant who knows the patient well to participate in informant-based questionnaires for the duration of the follow-up period.~* Living in independent or semi-independent living situation before the stroke.~* Fluent in English before the stroke.~* Provides written informed consent.~* Near visual acuity of at least 20/200 in at least one eye.~* Auditory acuity of at least having the ability to detect finger rubbing in at least one ear.~Exclusion Criteria:~* Parkinson's disease or restless leg syndrome.~* Partial or generalized seizures.~* No acute decompensated heart failure~* Routinely requiring daytime supplemental oxygen before the stroke; study participants on continuous positive air pressure (CPAP) for obstructive sleep apnea remain eligible.~* Gastrointestinal or genitourinary surgery within 1 month of screening.~* Gastrointestinal bleeding.~* Syncope or symptomatic bradycardia.~* Creatinine ≥ 3.5 mg/dL or requiring dialysis.~* Peptic ulcer disease.~* Asthma.~* Tracheostomy or endotracheal intubation.~* Taking donepezil or other acetylcholinesterase inhibitor at screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Donepezil (Type: EXPERIMENTAL): Participants received treatment with donepezil within 24 hours after the onset of ischemic stroke symptoms. Participants received donepezil 5 mg/day for 30 days, followed by an increase to 10 mg/day for 60 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sangustop® as Haemostatic Agent Versus a Carrier-Bound Fibrin Sealant During Liver Resection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion:~* Age: \> 18 years~* Gender: male / female~* Patients with an indication for liver resection (segmental or non-segmental)~* Willing and able to complete the clinical trial procedures, as described in the protocol~* Signed written informed consent to participate in this clinical trial~Exclusion:~* Presence or sequelae of coagulation disorder, liver cirrhosis, Klatskin tumor~* Concurrent participation in another clinical trial with a medical device or medicinal product or with interfering endpoints~* Concurrent or previous therapy with systemic pharmacologic agents promoting blood clotting including but not limited to tranexamix acid, activated factor VII, and aprotinine~* Known allergy or hypersensitivity to a component of the investigational treatments Sangustop® or TachoSil®, to riboflavin or to proteins of bovine origin~* Pregnancy or breast feeding~* Inability to understand the nature and the extent of the trial and the procedures required~* Missing signed written informed consent to participate in the study~Exclusion criteria to be checked during surgery (liver resection):~* Resection area estimated by operating surgeon \< 16cm2~* Infected wound area~* Persistant major bleeding after primary haemostasis~* No bleeding after resection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sangustop (Type: EXPERIMENTAL): None
- Tachosil (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study on Efficacy and Safety of Chondroitin Sulfate + Glucosamine Hydrochloride Versus Celecoxib in Knee Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 40 years of age~* Primary OA of the knee according to the American College of Rheumatology (ACR) criteria~* OA of radiological stages II or III according to Kellgren and Lawrence~* Patients with moderate-severe knee pain~Exclusion Criteria:~* Subjects with active malignancy of any type or history of a malignancy within the last five years~* Concurrent arthritic disease (antecedents and/or current signs) that could confound or interfere with the evaluation of pain efficacy such as chondrocalcinosis, Paget's disease of the ipsilateral limb to the target knee, rheumatoid arthritis, aseptic osteonecrosis, gout, septic arthritis, ochronosis, acromegaly, haemochromatosis, Wilson's disease, osteochondromatosis seronegative spondylo-arthropathy, mixed connective tissue disease, collagen vascular disease, psoriasis, inflammatory bowel disease~* Pain in other parts of the body greater than the knee pain that could interfere with the evaluation of the index joint~* Patients with fibromyalgia~* Subjects with a history of heart attack or stroke, or who have experienced chest pain related to heart disease, or who have had serious diseases of the heart~* Subjects with high risk of cardiovascular (CV) events~* Subjects with any active acute or chronic infections requiring antimicrobial therapy, or serious viral (e.g., hepatitis, herpes zoster, HIV positivity) or fungal infections~* Subjects with a history of recurrent Upper Gastrointestinal (UGI) ulceration or active inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis), a significant coagulation defect~* Subjects who have been diagnosed as having or have been treated for oesophageal, gastric, pyloric channel, or duodenal ulceration within 30 days prior to receiving the first dose of study medication~* Washout period for OA treatments before beginning the study.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chondroitin/Glucosamine (Droglican) (Type: EXPERIMENTAL): Active ingredients: Chondroitin sulfate, 200 mg and Glucosamine hydrochloride 250 mg.~Pharmacotherapeutic group: Other specific antirheumatic agents. Anatomical Therapeutic Chemical Classification System (ATC) code: M01CX.
- Celecoxib (Type: ACTIVE_COMPARATOR): Active ingredient: Celecoxib, 200 mg. Pharmacotherapeutic group: Coxibs. ATC code: M01AH.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Role of Oxidative Stress in the Cardiovascular Consequences of Sleep Apnea

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Completed sleep study - Older than 18~Exclusion Criteria:~* Hypertension~* Diabetes~* coronary disease~* Peripheral vascular disease~* High cholesterol~* Smoking~* Pregnancy~* Use of erectile dysfunction medications or supplements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control group: healthy individuals without OSA (Type: None): healthy individuals without OSA who are matched in weight and age to the participating OSA patients
- OSA group (Type: None): Patients in the OSA group receive CPAP for 12 weeks as part of their care. patients with OSA provide measures at baseline and after 12 weeks of CPAP treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Early Increase in Blood Flow (EIBS) in the Duodenum in Patients With Pancreatic Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older.~* Informed written consent.~* Patient scheduled for previously planned EGD with upper EUS~* Patients with known adenocarcinoma of the pancreas included in the cancer group~* Patients with abdominal imaging studies (e.g., CT abdomen or MRI abdomen) negative for malignancy in past 5 years included in the control group.~Exclusion Criteria:~* Unable to obtain biopsy specimen or fine-needle aspiration results of the pancreas lesion (e.g., coagulation disorder, inadequate sample)~* Presence of malignant lesion in the pancreas or duodenum other than pancreas adenocarcinoma (e.g., neuroendocrine tumor, gastrointestinal stromal tumor)~* Known familial disorder with high risk of pancreas cancer development (e.g., familial adenomatous polyposis syndrome, hereditary non-polyposis colorectal cancer syndrome, juvenile polyposis syndrome)~* Significant family history of pancreatic cancer (at least one first degree relative with pancreatic cancer)~* Presence of premalignant lesions (e.g., duodenal adenoma, pancreas intraductal papillary mucinous neoplasm)~* Active visible inflammation/ulcer in the stomach or the duodenum~* Patients with known chronic pancreatitis were excluded from cancer group. Chronic pancreatitis patients were allowed to be included in the control group only.~* Known pregnancy or sexually active females of childbearing age who are not practicing an accepted form of birth control.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cancer group (Type: EXPERIMENTAL): Participants in this group had pathologically confirmed pancreatic adenocarcinoma. They received an EGD with EUS. During the EUS, blood flow was measured in the duodenum with the 4D-ELF device.
- Control group (Type: OTHER): Participants in this group were without pancreatic adenocarcinoma. Participants in the control group received an EGD with EUS for the indication of abdominal pain. During the EUS, blood flow was measured in the duodenum with the 4D-ELF device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Very-Low Nicotine Cigarettes and Non-Daily Smokers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 18 years or older, and smoking cigarettes for at least 3 years~* smoking, on average, 4-27 days per month~* smoking at current rate for at least the previous 3 months~* willingness to try novel cigarettes~Exclusion Criteria:~* active plans to quit or actively seeking smoking cessation treatment in the next 3 months~* severe psychiatric disorders that may interfere with study procedures~* current, regular (i.e., monthly or more) use of nicotine replacement or other tobacco products, by self-report~* exclusive use of roll-your-own cigarettes (since the study uses manufactured cigarettes)~* \[for female participants\] being pregnant or breastfeeding, or planning to become pregnant, by self-report~* current use of medications such as Chantix (varenicline), Zyban, Wellbutrin, or bupropion for any purpose, including stopping smoking~* occurrence of heart attack, stroke, or angina in the past 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Very low nicotine content cigarettes (Type: EXPERIMENTAL): None
- Normal nicotine content cigarettes (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Short Course Nitrofurantoin for Acute Cystitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women 18-45 years of age who were nonpregnant, in good general health, and had symptoms of acute cystitis (dysuria) and a urine culture with ³102 cfu/ml of a uropathogen~Exclusion Criteria:~* Women who were pregnant, lactating, or not regularly contracepting or with diabetes, had known anatomic abnormalities of the urinary tract, allergy to any of the study drugs, recent (\<2 weeks) exposure to an oral or parenteral antimicrobial, or who were currently using prophylactic antibiotics were not eligible

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Nitrofurantoin 100mg BID x 5 days
- 2 (Type: ACTIVE_COMPARATOR): TMP/SMX DS BID x 3 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Morphine Slow-release Capsules in Substitution Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Minimum age: 18 years~* Fixed abode~* At least 26 weeks of treatment (up to date) receiving a minimum dose of 50 mg methadone or~  ≥ 25 mg/day levomethadone at inclusion. Patients on levomethadone must be informed and agree to be switched to methadone~* Mature and capable of acting responsibly, in possession of all mental faculties~* Female subjects must have a negative urine pregnancy test recorded prior to the first dose of study medication and regular negative urine pregnancy tests every 4 weeks. SUB9001 - Integrated Study Protocol 10/58 June 13, 2009~* Hormonal contraception (oral, transdermal, vaginal, intrauterine or subcutaneous) by women of child-bearing age~* No intention of reducing the substitute medication during the trial~* Acceptance of the trials rules and regulations~* Acceptance to participate in the study.~Exclusion criteria:~* (Desired) pregnancy during the trial~* Breastfeeding women~* Grave or acute somatic illnesses (e.g. cardio-vascular, serious kidney or liver affection (ALAT or ASAT \> 5x augmented)) or other somatic disorder~* If suffering from severe unstable mental health problems~* If MAO-Inhibitors or are being taken~* Intracranial injury~* Intracranial hypertension~* History of epilepsy~* Severe chronic obstructive lung disease~* Chronic respiratory failure~* Known hypersensitivity to morphine or methadone~* Pancreatitis~* Paralytic ileus~* Baseline QTc interval greater than 450 msec~* Long QT Syndrome~* Patients who have participated in another clinical research study involving a new chemical entity within 3 months of study entry~* Patients with pending imprisonment at the time of inclusion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sevre-Long™ (Type: ACTIVE_COMPARATOR): slow release oral morphine
- Methadone (Type: ACTIVE_COMPARATOR): Methodone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gastrointestinal Microbiota in Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of biliary atresia or primary sclerosing cholangitis.~* Clinical controls who are undergoing upper endoscopy or colonoscopy and do not have biliary atresia or primary sclerosing cholangitis.~* Subjects who have been on oral vancomycin for 1 year for biliary atresia or -~Exclusion Criteria:~* Patients that have taken antibiotics within the last 3 month will be excluded as this will alter the original bacterial flora.

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Oral Vancomycin (Type: EXPERIMENTAL): Vancocin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Papulopustular Rosacea Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The subject has papulopustular rosacea with an Investigator Global Assessment (IGA) score rated 3 (moderate) or 4 (severe),~2. The subject has at least 15 but not more than 70 inflammatory lesions (papules and pustules) on the face.~Exclusion Criteria:~1. The subject has particular forms of rosacea (rosacea conglobata, rosacea fulminans, isolated rhinophyma, isolated pustulosis of the chin) or other facial dermatoses that may be confounded with papulopustular rosacea, such as peri oral dermatitis, facial keratosis pilaris, seborrheic dermatitis, and acne,~2. The subject has rosacea with more than two nodules on the face.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CD5024 (Type: EXPERIMENTAL): CD5024 1% Cream
- CD5024 Vehicle (Type: PLACEBO_COMPARATOR): CD5024 Vehicle Cream

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete